Cancer :

1. Tumor development begins when some cell (orange) within a normal population (beige) sustains
a genetic mutation that increases its propensity to proliferate when it would normally rest.
2. The altered cell and its descendants continue to look normal, but they reproduce too much—a
condition termed hyperplasia. After years, one in a million of these cells (pink) suffers another
mutation that further loosens controls on cell growth.
3. In addition to proliferating excessively, the offspring of this cell appear abnormal in shape and in
orientation; the tissue is now said to exhibit dysplasia. Once again, after a time, a rare mutation
that alters cell behavior occurs (purple).
4. The affected cells become still more abnormal in growth and appearance. If the tumor has not
yet broken through any boundaries between tissues, it is called in situ cancer. This tumor may
remain contained indefinitely; however, some cells may eventually acquire additional mutations
(blue).
5. If the genetic changes allow the tumor to begin invading underlying tissue and to shed cells into
the blood or lymph, the mass is considered to have become malignant. The renegade cells are
likely to establish new tumors (metastases) throughout the body; these may become lethal by
disrupting a vital organ.

impressive evidence has uncovered the destination of stimulatory and inhibitory pathways in
the cell. They converge on a molecular apparatus in the cell nucleus that is often referred to as
the cell cycle clock. The clock is the executive decision maker of the cell, and it apparently runs
amok in virtually all types of human cancer. In the normal cell, the clock integrates the mixture
of growthregulating signals received by the cell and decides whether the cell should pass
through its life cycle. If the answer is positive, the clock leads the process. The cell cycle is
composed of four stages.
In the G1 (gap 1) phase, the cell increases in size and prepares to copy its DNA. This copying
occurs in the next stage, termed S (for synthesis), and enables the cell to duplicate precisely its
complement of chromosomes. After the chromosomes are replicated, a second gap period,
termed G2, follows during which the cell prepares itself for M (mitosis)—the time when the
enlarged parent cell finally divides in half to produce its two daughters, each of which is
endowed with a complete set of chromosomes.
The new daughter cells immediately enter G1 and may go through the full cycle again.
Alternatively, they may stop cycling temporarily or permanently. The cell cycle clock programs
this elaborate succession of events by means of a variety of molecules.
Its two essential components, cyclins and cyclin-dependent kinases (CDKs), associate with one
another and initiate entrance into the various stages of the cell cycle. In G1, for instance, D-type
cyclins bind to CDKs 4 or 6, and the resulting complexes act on a powerful growth-inhibitory
molecule—the protein known as pRB.
This action releases the braking effect of pRB and enables the cell to progress into late G1 and
thence into S (DNA synthesis) phase [see b in box below]. Various inhibitory proteins can
restrain forward movement through the cycle. Among them are p15 (mentioned earlier) and
 p16, both of which block the activity of the CDK partners of cycclin D, thus preventing the
advance of the cell from G1 into S. Another inhibitor of CDKs, termed p21, can act throughout
the cell cycle.
P21 is under control of a tumor suppressor protein, p53, that monitors the health of the cell, the
integrity of its chromosomal DNA and the successful completion of the different steps in the
cycle. Breast cancer cells often produce excesses of cyclin D and cyclin E. In many cases of
melanoma, skin cells have lost the gene encoding the braking protein p16.
Half of all types of human tumors lack a functional p53 protein. And in cervical cancers
triggered by infection of cells with a human papillomavirus, both the pRB and p53 proteins are
frequently disabled, eliminating two of the clock’s most vital restraints.
The end result in all these cases is that the clock begins to spin out of control, ignoring any
external warnings to stop. If investigators can devise ways to impose clamps on the cyclins and
CDKs active in the cell cycle, they may be able to halt cancer cells in their tracks.

 An explosion of research is uncovering the long-hidden molecular underpinnings of

Mechanisms of Carcinogenesis

Mutations.

Mutations in several critical genes can lead to tumors (7). Mutations in the tumor-suppressor gene p53
are found in about half of human tumors. The p53 protein guards a cell cycle checkpoint, and
inactivation of p53 allows uncontrolled cell division.

DNA Lesions

. DNA lesions (damaged bases or chromosome breaks) have a certain probability of giving rise to
mutations when the cell divides. Endogenous DNA damage is high (8). An exogenous mutagen produces
an increment in lesions over the background rate of endogenous lesions. The mutagenic effectiveness of
a particular lesion depends on its rate of excision by DNA repair enzymes and on the probability that it
gives rise to a mutation when the cell divides.

Cell Division. This is a critical factor in mutagenesis, because when the cell divides a DNA lesion can give
rise to a point mutation, deletion, or translocation (9- 11). Thus, an important factor in the mutagenic
effect of an agent is the increment it causes over the background cell division rate in those cells that
matter. Those cells that appear to matter most for cancer are the stem cells, which are not discarded,
whereas their daughter cells are. Increasing the cell division rate of stem cells increases mutation and
therefore cancer. As expected, there is little cancer in nondividing cells. Increased cell division, and
therefore an increased risk for cancer, can be caused by such diverse agents as increased levels of
particular hormones (12), excess calories, chronic inflammation, or chemicals at doses causing cell
division (13-16). If both the rate of DNA lesions and cell division are increased, then there will be a
multiplicative increase in mutagenesis, for example, by high doses of a mutagen which also increases cell
division through cell killing and consequent cell replacement. Chronic dosing at high levels of chemicals
that do not damage DNA can also cause cell killing and consequent cell division and thus increase
cancer. Studies of cell division in stem cells, and the signaling systems responsible for stem-cell
proliferation, are active and important areas of research.

Cell Cycle Checkpoints. These checkpoints prevent division of cells with too many DNA lesions, thus
inhibiting the formation of mutations. This defense, likeDNA repair, is not perfect. The sensing of lesions
in transcribed genes is done by the transcription apparatus that makes mRNA (17, 18). The presence of
lesions appears to induce DNA repair and also to halt cell division at a cell cycle checkpoint. The
mechanism may be that the p53 protein, which controls the G1-to-S checkpoint, is associated with the
replication and repair protein RPA (19, 20). When DNA damage occurs, RPA appears to bind to single-
strand DNA and release p53 (19, 20), which in turn causes a block of cell division at the checkpoint, thus
preventing conversion of lesions to mutations (M. Botchan, personal communication). In addition, p53 is
involved in triggering cell death (apoptosis) (21), so that a higher level of DNA lesions may lead to an
apoptotic signal (22).

Defense Systems.

Defense systems such as the glutathione transferases protect DNA against mutagens. These defenses
are almost all inducible and, thus, buffer cells from increments in reactive electrophilic chemicals that
can cause DNA lesions (23). DNA repair enzymes, almost all of which are inducible, buffer the cell against
increments in DNA lesions. Therefore, the effect of a particular chemical insult is dependent on the level
of each defense, which in turn is dependent on the past history of exposure. Defenses can be partially
disabled by lack of particular micronutrients in the diet (e.g., antiox

 The causes and prevention of cancer

The deviations from normal of malignant cells can conveniently be discussed, from the point of view of
the cell surface, in the following categories.

1. Local invasion. The malignant cells move outward from the focus of origin of the neoplasm,
insinuating themselves amongst the surrounding normal cells.
2. Metastasis. As a result of invasion the malig nant cells reach moving body fluids, by which they are
passively transported and become widely dis seminated.

3. Disorganization. The malignant cells as they multiply fail to form tissue of the arrangement
characteristic of their normal counterparts.

4. Persistent growth. The malignant cell popu lation keeps up a continuous growth by mitosis.

 The Surface Properties of Cancer Cells: A Review

Cancer is a global health problem responsible for one in six deaths worldwide. In 2020, there were an
estimated 19.3 million new cancer cases and about 10 million cancer deaths globally. Cancer is a very
complicated sequence of disease conditions progressing gradually with a generalized loss of growth
control.

 New approaches and procedures for cancer treatment: Current perspectives

Alterations in the cellular genome affecting the expression or function of genes controlling cell growth
and differentiation are considered to be the main cause of cancer. Molecular cancer research aims at
identifying the genes that are altered in the various tumor types and elucidating the role of these genes
in carcinogenesis.

 as Oncogenes in Human Cancer: A Review(Johannes L. Bos)

Cancer cells arise due to the imbalance in the body functions and they invade and
infect the normal cells. Cancer is not one disease; rather it is a group of various
diseases. The present chapter includes explicit information on cancer types such as
cancer of blood, lungs, colon and rectum, prostate, skin, breast, uterus, thyroid,
lymphatic system, etc. Cancers are being treated by various methods which include
chemotherapy, precision medicine, radiation therapy, surgery, stem cell transplant,
hormone therapy, immune therapy, and targeted therapy. In some cases, cancer can
be treated by single method, but mostly several methods are used to cure the
 disease. Moreover, the treatment specifically depends upon the stage and type of
cancer. In chemotherapy and radiotherapy, survival rates are usually very low
because of their undesirable side effects on human health

Types of Cancer

 First Online: 08 January 2020
 pp 53–150
(herbs for cancer treatment )

Types of cancer

Lung (and trachea and bronchus)

Liver (and intrahepatic bile ducts)

Stomach

Breast

Colon

Esophagus

Pancreas

Thyroid

Prostate

Cervix uteri

Rectum

Leukemia

Non-Hodgkin’s lymphoma

Bladder

Kidney
 Current Cancer Epidemiology
 Camilla Mattiuzzi1 , Giuseppe Lippi2,
 Journal of Epidemiology and Global Health Vol. 9(4); December (2019), pp. 217–222